The kidney as a target organ in pharmaceutical research

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 244-259

  Prunotto, Marco ^a,d   Gabbiani, Giulio ^b   Pomposiello, Silvia ^c   Ghiggeri, Gianmarco ^d   Moll, Solange ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BOSENTAN; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALKIREN; ENDOTHELIN; ENKEPHALINASE INHIBITOR; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILEPATRIL; IMIDAPRIL; OMAPATRILAT; RENIN; RENIN INHIBITOR; RHO KINASE INHIBITOR; SMALL INTERFERING RNA; STEROID; TRANSFORMING GROWTH FACTOR BETA 1 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; VITAMIN D; VITAMIN D DERIVATIVE; ZALKIREN;

ACUTE KIDNEY FAILURE; ALPORT SYNDROME; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIURESIS; DRUG DESIGN; DRUG INDUSTRY; DRUG INHIBITION; DRUG MEGADOSE; DRUG RESEARCH; EPIDEMIOLOGICAL DATA; EPITHELIAL MESENCHYMAL TRANSITION; FLUID RETENTION; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATORY CELL; KIDNEY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE; LIVER TOXICITY; MORBIDITY; MORTALITY; MYOFIBROBLAST; NEPHRITIS; NEPHROSCLEROSIS; NEPHROTIC SYNDROME; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; STEROID THERAPY; VASODILATATION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; FIBROSIS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RESEARCH;

EID: 79952451067     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.11.011     Document Type: Review

References (205)

1. K. Tryggvason, and J. Wartiovaara How does the kidney filter plasma? Physiology (Bethesda) 20 2005 96 101 (Pubitemid 40627550)
2. T. Ali Incidence and outcomes in acute kidney injury: a comprehensive population-based study J. Am. Soc. Nephrol. 18 2007 1292 1298 (Pubitemid 46536915)
3. C.Y. Hsu Community-based incidence of acute renal failure Kidney Int. 72 2007 208 212
4. S.H. Hou Hospital-acquired renal insufficiency: a prospective study Am. J. Med. 74 1983 243 248 (Pubitemid 13192180)
5. J. Coresh Prevalence of chronic kidney disease in the United States JAMA 298 2007 2038 2047 (Pubitemid 350074801)
6. N. Lameire Chronic kidney disease: a European perspective Kidney Int. 99 Suppl. 2005 S30 S38
7. M.A. Venkatachalam Acute kidney injury: a springboard for progression in chronic kidney disease Am. J. Physiol. Renal Physiol. 298 2010 F1078 F1094
8. J.P. Lafrance Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort Nephrol. Dial. Transplant. 7 2010 2203 2209
9. S.G. Coca Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis Am. J. Kidney Dis. 53 2009 961 973
10. H. Azuma Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney Transplantation 64 1997 190 197 (Pubitemid 27332657)
11. H. Azuma Initial ischemia/reperfusion injury influences late functional and structural changes in the kidney Transplant. Proc. 29 1997 1528 1529 (Pubitemid 27126302)
12. H.S. Mackenzie Renal mass as a determinant of late allograft outcome: insights from experimental studies in rats Kidney Int. Suppl. 52 1995 S38 S42
13. G. Remuzzi Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury Curr. Opin. Nephrol. Hypertens. 4 1995 339 342
14. K. Tryggvason Nck links nephrin to actin in kidney podocytes Cell 125 2006 221 224
15. C. Faul The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A Nat. Med. 14 2008 931 938
16. D.J. Leehey Role of angiotensin II in diabetic nephropathy Kidney Int. Suppl. 77 2000 S93 S98
17. T. Suzuki Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat Am. J. Pathol. 158 2001 75 85 (Pubitemid 32096473)
18. G. Gabbiani Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction Experientia 27 1971 549 550
19. J.J. Tomasek Myofibroblasts and mechano-regulation of connective tissue remodelling Nat. Rev. Mol. Cell Biol. 3 2002 349 363 (Pubitemid 34619269)
20. B. Hinz The myofibroblast: one function, multiple origins Am. J. Pathol. 170 2007 1807 1816 (Pubitemid 47339255)
21. A. Desmouliere Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar Am. J. Pathol. 146 1995 56 66
22. E.M. Zeisberg Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition J. Am. Soc. Nephrol. 19 2008 2282 2287
23. J.P. Thiery Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
24. H. Acloque Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease J. Clin. Invest. 119 2009 1438 1449
25. E.M. Zeisberg Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat. Med. 13 2007 952 961 (Pubitemid 47222040)
26. M. Zeisberg, and J. Duffield Resolved: EMT produces fibroblasts in the kidney J. Am. Soc. Nephrol. 21 2010 1247 1253
27. L. Yang Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury Nat. Med. 16 2010 535 543
28. K. Udo Adipose tissue explants and MDCK cells reciprocally regulate their morphogenesis in co-culture Kidney Int. 78 2010 60 68
29. M. Sharma Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ Breast Cancer Res. Treat. 2009
30. M. Prunotto, and S. Moll The emerging concept of a fibrotic microenvironment in CKD Kidney Int. 79 1 2011 135
31. R. Koesters Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells Am. J. Pathol. 177 2010 632 643
32. M. Schmidt Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma J. Immunol. 171 2003 380 389 (Pubitemid 36745311)
33. A. Heidland Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension J. Hum. Hypertens. 15 2001 5 16 (Pubitemid 32106763)
34. V.M. Campese Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr. Opin. Nephrol. Hypertens. 9 2000 143 147 (Pubitemid 30131445)
35. D. de Zeeuw Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int. 65 2004 2309 2320 (Pubitemid 38670018)
36. M. Abbate Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts Kidney Int. 61 2002 2066 2077 (Pubitemid 34539324)
37. T. Bertani Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy Kidney Int. 30 1986 488 496 (Pubitemid 16000793)
38. T. Bertani Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content Lab. Invest. 60 1989 196 204 (Pubitemid 19072403)
39. G. Remuzzi, and T. Bertani Pathophysiology of progressive nephropathies N. Engl. J. Med. 339 1998 1448 1456 (Pubitemid 28516069)
40. R.J. Baines, and N.J. Brunskill The molecular interactions between filtered proteins and proximal tubular cells in proteinuria Nephron Exp. Nephrol. 110 2008 e67 e71
41. A.A. Eddy, and C.M. Giachelli Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria Kidney Int. 47 1995 1546 1557
42. Y. Wang Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein J. Am. Soc. Nephrol. 8 1997 1537 1545 (Pubitemid 27496471)
43. A.V. Cybulsky Endoplasmic reticulum stress in proteinuric kidney disease Kidney Int. 77 2009 187 193
44. S. Markan Up regulation of the GRP-78 and GADD-153 and down regulation of Bcl-2 proteins in primary glomerular diseases: a possible involvement of the ER stress pathway in glomerulonephritis Mol. Cell. Biochem. 324 2009 131 138
45. T. Ohse Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells Kidney Int. 70 2006 1447 1455 (Pubitemid 44527314)
46. X. Wu Albumin overload induces apoptosis in renal tubular epithelial cells through a CHOP-dependent pathway OMICS 14 2010 61 73
47. M.T. Lindenmeyer Proteinuria and hyperglycemia induce endoplasmic reticulum stress J. Am. Soc. Nephrol. 19 2008 2225 2236
48. L. Ulianich ER stress is associated with dedifferentiation and an epithelial-to-mesenchymal transition-like phenotype in PC Cl3 thyroid cells J. Cell Sci. 121 2008 477 486 (Pubitemid 351405056)
49. K. Seki Mouse Snail family transcription repressors regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan J. Biol. Chem. 278 2003 41862 41870 (Pubitemid 37310447)
50. M. Prunotto Endocellular polyamine availability modulates epithelial-to-mesenchymal transition and unfolded protein response in MDCK cells Lab. Invest. 90 2010 929 939
51. K. Dahan A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin J. Am. Soc. Nephrol. 14 2003 2883 2893 (Pubitemid 37305651)
52. S. Tang Role of complement in tubulointerstitial injury from proteinuria Kidney Blood Press. Res. 25 2002 120 126 (Pubitemid 34665215)
53. P. Boor Treatment targets in renal fibrosis Nephrol. Dial. Transplant. 22 2007 3391 3407 (Pubitemid 350212482)
54. G. Camussi In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney J. Immunol. 128 1982 1659 1663 (Pubitemid 12193020)
55. L. Biancone Alternative pathway activation of complement by cultured human proximal tubular epithelial cells Kidney Int. 45 1994 451 460 (Pubitemid 24065080)
56. M. Nangaku Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure Intern. Med. 43 2004 9 17 (Pubitemid 38208370)
57. Y. Morita The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis J. Am. Soc. Nephrol. 8 1997 1363 1372 (Pubitemid 27491226)
58. G.K. Rangan C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria Kidney Int. 67 2005 492 503 (Pubitemid 40139841)
59. T.R. Welch C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis Clin. Exp. Immunol. 130 2002 43 48
60. P. Boor Complement C5 mediates experimental tubulointerstitial fibrosis J. Am. Soc. Nephrol. 18 2007 1508 1515 (Pubitemid 46717517)
61. L. Bao Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure J. Am. Soc. Nephrol. 18 2007 811 822 (Pubitemid 46434498)
62. K. Spett Pathological affect Neurol. Neurochir. Psychiatr. Pol. 15 1965 573 576
63. C. Chatziantoniou, and J.C. Dussaule Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am. J. Physiol. Renal Physiol. 289 2005 F227 F234
64. M. Abbate Nephrotoxicity of increased glomerular protein traffic Nephrol. Dial. Transplant. 14 1999 304 312 (Pubitemid 29062783)
65. Y.J. Choi Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor Hum. Pathol. 31 2000 1491 1497
66. J.T. Norman Hypoxia promotes fibrogenesis in human renal fibroblasts Kidney Int. 58 2000 2351 2366
67. J.T. Norman Hypoxia-induced changes in extracellular matrix metabolism in renal cells Exp. Nephrol. 7 1999 463 469 (Pubitemid 29517356)
68. K. Manotham Transdifferentiation of cultured tubular cells induced by hypoxia Kidney Int. 65 2004 871 880 (Pubitemid 38251062)
69. G. Remuzzi Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes J. Clin. Invest. 116 2006 288 296 (Pubitemid 43228342)
70. G. Remuzzi The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease Kidney Int. 68 2005 S57 S65
71. X.R. Huang Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease J. Am. Soc. Nephrol. 14 2003 1738 1747 (Pubitemid 36750469)
72. A.T. Lely Renal ACE2 expression in human kidney disease J. Pathol. 204 2004 587 593 (Pubitemid 39585958)
73. R.V. Durvasula Activation of a local tissue angiotensin system in podocytes by mechanical strain Kidney Int. 65 2004 30 39 (Pubitemid 38037489)
74. G. Wolf Aminopeptidase A: a key enzyme in the intrarenal degradation of angiotensin II Exp. Nephrol. 5 1997 364 369 (Pubitemid 27475568)
75. M. Cesari Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases J. Hypertens. 20 2002 793 799 (Pubitemid 34913648)
76. B. Pilz Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats Hypertension 46 2005 569 576 (Pubitemid 41376839)
77. G. Nguyen The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology Curr. Opin. Nephrol. Hypertens. 16 2007 129 133
78. M.A. Weber Vasopeptidase inhibitors Lancet 358 2001 1525 1532 (Pubitemid 33055710)
79. O. Gross Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688 Kidney Int. 68 2005 456 463 (Pubitemid 43323100)
80. A. Benigni Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy Kidney Int. 66 2004 1959 1965 (Pubitemid 41094320)
81. J.B. Kostis Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am. J. Hypertens. 17 2004 103 111 (Pubitemid 38125125)
82. G. Wolf, and E. Ritz Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications Kidney Int. 67 2005 799 812 (Pubitemid 41623305)
83. M. Adamczak Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats J. Am. Soc. Nephrol. 14 2003 2833 2842 (Pubitemid 37305646)
84. J.C. Mason The statins-therapeutic diversity in renal disease? Curr. Opin. Nephrol. Hypertens. 14 2005 17 24
85. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
86. S. Etienne-Manneville, and A. Hall Rho GTPases in cell biology Nature 420 2002 629 635 (Pubitemid 36764489)
87. C. Zoja How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach J. Am. Soc. Nephrol. 13 2002 2898 2908 (Pubitemid 35386909)
88. C. Zoja Adding a statin to a combination of Ace inhibitor and Arb normalizes proteinuria in experimental diabetes which translates into full renoprotection Am. J. Physiol. Renal Physiol. 299 2010 F1203 F1211
89. Y. Zhang Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system J. Am. Soc. Nephrol. 21 2010 966 973
90. K. Mirkovic Vitamin D in chronic kidney disease: new potential for intervention Curr. Drug Targets 2010 doi:BSP/CDT/E-Pub/00158
91. M.R. Haussler The nuclear vitamin D receptor: biological and molecular regulatory properties revealed J. Bone Miner. Res. 13 1998 325 349 (Pubitemid 28146215)
92. Y.C. Li Renoprotective effects of vitamin D analogs Kidney Int. 78 2009 134 139
93. R.M. Fryer Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice Nephron Physiol. 106 2007 76 81
94. Y.C. Li 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system J. Clin. Invest. 110 2002 229 238 (Pubitemid 34787360)
95. W. Yuan 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter J. Biol. Chem. 282 2007 29821 29830 (Pubitemid 350035242)
96. J. Sun Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor Am. J. Physiol. Endocrinol. Metab. 291 2006 E315 E322
97. D.K. Deb 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway Am. J. Physiol. Renal Physiol. 296 2009 F1212 F1218
98. C. Guijarro, and J. Egido Transcription factor-kappa B (NF-kappa B) and renal disease Kidney Int. 59 2001 415 424 (Pubitemid 32157906)
99. D. Zehnder Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation Kidney Int. 74 2008 1343 1353
100. K. Makibayashi A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis Am. J. Pathol. 158 2001 1733 1741 (Pubitemid 32422938)
101. M. Mizobuchi Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats J. Am. Soc. Nephrol. 18 2007 1796 1806 (Pubitemid 46870316)
102. Z. Zhang Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase Proc. Natl. Acad. Sci. U.S.A. 105 2008 15896 15901
103. X. Tan Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy J. Am. Soc. Nephrol. 17 2006 3382 3393 (Pubitemid 44865281)
104. C.R. Doorenbos Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism Nat. Rev. Nephrol. 5 2009 691 700
105. H.J. Lambers Heerspink The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics Am. J. Nephrol. 30 2009 280 286
106. U. Thiem VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome Trials 10 2009 36
107. K. Nagatoya Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction Kidney Int. 61 2002 1684 1695 (Pubitemid 34437922)
108. T. Nishikimi Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats J. Hypertens. 22 2004 1787 1796 (Pubitemid 39141972)
109. Y. Ishikawa Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats Hypertension 47 2006 1075 1083 (Pubitemid 44289164)
110. F. Peng RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease Diabetes 57 2008 1683 1692
111. T. Leung A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes J. Biol. Chem. 270 1995 29051 29054
112. M. Amano Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase Science 275 1997 1308 1311 (Pubitemid 27114159)
113. Y. Takai Rho as a regulator of the cytoskeleton Trends Biochem. Sci. 20 1995 227 231
114. Y. Takai Small GTP-binding proteins Physiol. Rev. 81 2001 153 208 (Pubitemid 32098004)
115. M. Uehata Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 1997 990 994 (Pubitemid 27485693)
116. Y. Takeda Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction Hypertens. Res. 33 2010 965 973
117. M. Nishida, and K. Hamaoka Macrophage phenotype and renal fibrosis in obstructive nephropathy Nephron Exp. Nephrol. 110 2008 e31 e36
118. S.D. Ricardo Macrophage diversity in renal injury and repair J. Clin. Invest. 118 2008 3522 3530
119. E. Song Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts Cell. Immunol. 204 2000 19 28
120. P. Jungers Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients Nephrol. Dial. Transplant. 16 2001 307 312 (Pubitemid 32123919)
121. S. Kuriyama Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 77 1997 176 185 (Pubitemid 27440408)
122. D.H. Kang Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function J. Am. Soc. Nephrol. 12 2001 1448 1457
123. T. Hofer Oxygen sensing, HIF-1alpha stabilization and potential therapeutic strategies Pflugers Arch. 443 2002 503 507 (Pubitemid 34185054)
124. D.F. Higgins Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition J. Clin. Invest. 117 2007 3810 3820 (Pubitemid 350224091)
125. Y.R. Song Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney Nephrol. Dial. Transplant. 25 2010 77 85
126. M. Kapoor GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism J. Clin. Invest. 118 2008 3279 3290
127. D. Gradl The Wnt/Wg signal transducer beta-catenin controls fibronectin expression Mol. Cell. Biol. 19 1999 5576 5587 (Pubitemid 29339915)
128. T. Brabletz Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer Am. J. Pathol. 155 1999 1033 1038 (Pubitemid 29488909)
129. I. Hwang Wnt/beta-catenin signaling: a novel target for therapeutic intervention of fibrotic kidney disease Arch. Pharm. Res. 32 2009 1653 1662
130. W. He Wnt/beta-catenin signaling promotes renal interstitial fibrosis J. Am. Soc. Nephrol. 20 2009 765 776
131. M. Iwano EMT and TGF-beta in renal fibrosis Front. Biosci. 2 2010 229 238
132. W.A. Border, and N.A. Noble Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy Kidney Int. 54 1998 1390 1391 (Pubitemid 28449932)
133. E. Gagliardini, and A. Benigni Therapeutic potential of TGF-beta inhibition in chronic renal failure Expert Opin. Biol. Ther. 7 2007 293 304 (Pubitemid 46383473)
134. C.P. Denton Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum. 56 2007 323 333 (Pubitemid 46106206)
135. H.Y. Lan Smad7 as a therapeutic agent for chronic kidney diseases Front. Biosci. 13 2008 4984 4992
136. H.Y. Lan Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model J. Am. Soc. Nephrol. 14 2003 1535 1548 (Pubitemid 36687055)
137. Y. Terada Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney Kidney Int. 61 Suppl. 1 2002 S94 S98
138. L.J. Ma Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice Am. J. Pathol. 163 2003 1261 1273
139. K. Hahm Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse Am. J. Pathol. 170 2007 110 125 (Pubitemid 47342405)
140. E. Ozkaynak OP-1 cDNA encodes an osteogenic protein in the TGF-beta family EMBO J. 9 1990 2085 2093
141. A.T. Dudley A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye Genes Dev. 9 1995 2795 2807
142. G. Luo BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning Genes Dev. 9 1995 2808 2820
143. S. Vukicevic Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat J. Clin. Invest. 102 1998 202 214 (Pubitemid 28323847)
144. J. Lin Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease Nat. Med. 11 2005 387 393 (Pubitemid 40562328)
145. M. Tanaka Loss of the BMP antagonist U. S. A.G-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome J. Clin. Invest. 120 2010 768 777
146. M. Tanaka Expression of BMP-7 and U. S. A.G-1 (a BMP antagonist) in kidney development and injury Kidney Int. 73 2008 181 191
147. G. Carvajal Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy Transplant. Proc. 40 2008 734 739 (Pubitemid 351608666)
148. V. Dolan Gremlin - a putative pathogenic player in progressive renal disease Expert Opin. Ther. Targets 7 2003 523 526 (Pubitemid 37063339)
149. M. Zeisberg BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury Nat. Med. 9 2003 964 968 (Pubitemid 36889942)
150. P. Archdeacon, and R.K. Detwiler Bone morphogenetic protein 7 (BMP7): a critical role in kidney development and a putative modulator of kidney injury Adv. Chronic Kidney Dis. 15 2008 314 320 (Pubitemid 351822600)
151. P. Boor Renal fibrosis: novel insights into mechanisms and therapeutic targets Nat. Rev. Nephrol. 6 2010 643 656
152. Iekushi, K. et al. Hepatocyte growth factor attenuates renal fibrosis through TGF-beta1 suppression by apoptosis of myofibroblasts. J. Hypertens. (2010) Sep 11
153. C. Dai Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria Kidney Int. 77 2010 962 973
154. S. Mizuno HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease Front. Biosci. 13 2008 7072 7086
155. L.J. Ma, and A.B. Fogo Modulation of glomerulosclerosis Semin. Immunopathol. 29 2007 385 395 (Pubitemid 350077258)
156. D. Delaroche Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts J. Biol. Chem. 285 2010 7712 7721
157. B. Julien Antifibrogenic role of the cannabinoid receptor CB2 in the liver Gastroenterology 128 2005 742 755 (Pubitemid 40585376)
158. H.E. Wasmuth, and C. Trautwein CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis Hepatology 45 2007 543 544 (Pubitemid 46374610)
159. J. Mann MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis Gastroenterology 138 2010 705 714 714, e701-e704
160. A.K. Ghosh Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma Arthritis Rheum. 50 2004 1305 1318 (Pubitemid 38480842)
161. T. Kawai PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta Lab. Invest. 89 2009 47 58
162. A. Douglass Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury J. Hepatol. 49 2008 88 98
163. M. Murea Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function Kidney Int. 78 2010 514 522
164. L. Lasagni Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders Stem Cells 28 9 2010 1674 1685
165. T. Niranjan The Notch pathway in podocytes plays a role in the development of glomerular disease Nat. Med. 14 2008 290 298 (Pubitemid 351347919)
166. L. Lasagni Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders Stem Cells 28 2010 1674 1685
167. P. Ronco, and C. Chatziantoniou Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives Kidney Int. 74 2008 873 878
168. P. Ronco Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin Semin. Nephrol. 27 2007 352 362 (Pubitemid 46802918)
169. I. Bergheim Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis J. Pharmacol. Exp. Ther. 316 2006 592 600 (Pubitemid 43130985)
170. T. Oda PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction Kidney Int. 60 2001 587 596 (Pubitemid 32678902)
171. S. Matsuo Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice Kidney Int. 67 2005 2221 2238 (Pubitemid 41623383)
172. A.A. Eddy, and A.B. Fogo Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action J. Am. Soc. Nephrol. 17 2006 2999 3012 (Pubitemid 44707760)
173. Y. Huang A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis J. Clin. Invest. 112 2003 379 388 (Pubitemid 38063766)
174. Y. Huang A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy J. Am. Soc. Nephrol. 19 2008 329 338 (Pubitemid 351240654)
175. V. Barry-Hamilton Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat. Med. 16 2010 1009 1017
176. O. Gross Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease Matrix Biol. 29 2010 346 356
177. M. Flamant Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease J. Am. Soc. Nephrol. 17 2006 3374 3381 (Pubitemid 44865280)
178. R. Lee Localization of discoidin domain receptors in rat kidney Nephron Exp. Nephrol. 97 2004 e62 e70
179. W.H. Hahn Linkage and association study of discoidin domain receptor 1 as a novel susceptibility gene for childhood IgA nephropathy Int. J. Mol. Med. 25 2010 785 791
180. M.J. Ryan HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney Kidney Int. 45 1994 48 57 (Pubitemid 24045991)
181. R.N. Hull The origin and characteristics of a pig kidney cell strain, LLC-PK In Vitro 12 1976 670 677 (Pubitemid 8084967)
182. R. Nielsen Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin J. Am. Soc. Nephrol. 9 1998 1767 1776 (Pubitemid 28443473)
183. M.J. Rindler Retention of differentiated properties in an established dog kidney epithelial cell line (MDCK) J. Cell Biol. 81 1979 635 648 (Pubitemid 9202331)
184. J. Reiser Toward the development of podocyte-specific drugs Kidney Int. 77 2010 662 668
185. P. Mundel Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes J. Cell Biol. 139 1997 193 204 (Pubitemid 27444091)
186. J.D. Sraer Stable cell lines of T-SV40 immortalized human glomerular mesangial cells Kidney Int. 49 1996 267 270
187. K. MacKay Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice Kidney Int. 33 1988 677 684 (Pubitemid 18083117)
188. K. Nitta, and N. Horiba An immortalized rat mesangial cell line In Vitro Cell. Dev. Biol. Anim. 33 1997 156 157
189. T.D. Hewitson Small animal models of kidney disease: a review Methods Mol. Biol. 466 2009 41 57
190. S.N. Heyman Animal models of acute tubular necrosis Curr. Opin. Crit. Care 8 2002 526 534 (Pubitemid 35388207)
191. X. Yao Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124 (Pubitemid 47262919)
192. P. Balakumar Experimental models for nephropathy J. Renin Angiotensin Aldosterone Syst. 9 2008 189 195
193. H.J. Zhao Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice J. Am. Soc. Nephrol. 17 2006 2664 2669 (Pubitemid 44484656)
194. T. Nakagawa A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism Clin. Nephrol. 71 2009 103 109
195. B.C. Astor Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population Am. J. Epidemiol. 167 2008 1226 1234 (Pubitemid 351670638)
196. B. Hocher, and M. Paul Transgenic animal models for the analysis of the renal endothelin system Nephrol. Dial. Transplant. 15 2000 935 937 (Pubitemid 30410358)
197. D.E. Kohan Endothelin, hypertension and chronic kidney disease: new insights Curr. Opin. Nephrol. Hypertens. 19 2010 134 139
198. L.D. Truong Cell apoptosis and proliferation in experimental chronic obstructive uropathy Kidney Int. 50 1996 200 207 (Pubitemid 26323714)
199. S. Klahr Urinary tract obstruction Semin. Nephrol. 21 2001 133 145 (Pubitemid 32230546)
200. P.X. Wang, and P.W. Sanders Mechanism of hypertensive nephropathy in the Dahl/Rapp rat: a primary disorder of vascular smooth muscle Am. J. Physiol. Renal Physiol. 288 2005 F236 F242
201. L.J. Ma, and A.B. Fogo Model of robust induction of glomerulosclerosis in mice: importance of genetic background Kidney Int. 64 2003 350 355 (Pubitemid 36714190)
202. D. Schlondorff Choosing the right mouse model for diabetic nephropathy Kidney Int. 77 2010 749 750
203. F.C. Brosius III Mouse models of diabetic nephropathy J. Am. Soc. Nephrol. 20 2009 2503 2512
204. G.H. Tesch, and T.J. Allen Rodent models of streptozotocin-induced diabetic nephropathy Nephrology 12 2007 261 266 (Pubitemid 46718209)
205. D.H. Kang Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor Am. J. Physiol. Renal Physiol. 280 2001 F727 F736